Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Wiener Medizinische Wochenschrift
Erschienen in:

26.09.2016 | brief report

Up-date on the NeoVitaA Trial: Obstacles, challenges, perspectives, and local experiences

verfasst von: Prof. Dr. med. Sascha Meyer, Prof. Dr. med. Ludwig Gortner, NeoVitaA Trial investigators

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 11-12/2017

Einloggen, um Zugang zu erhalten

Summary

The aim of the NeoVitaA Trial is to assess the role of postnatal additional high-dose oral vitamin A supplementation for 28 days in reducing Bronchopulmonary dysplasia (BPD) or death in extremely low birth weight (ELBW) infants at 36 weeks postmenstrual age (PMA). All infants (both intervention and control group) will be provided with basic vitamin A (1000 IU/kg/day) in addition to trial intervention.
In this short communication, we will give an up-date on obstacles, challenges as well as perspectives and potential solutions when putting into place a multicenter, double-blind, randomized trial in this cohort of extremely susceptible infants.
Vorheriger Artikel Acute osteomyelitis and septic arthritis in children
Nächster Artikel ESPED-Erhebung: TSC-Erkrankung bei Kindern und Jugendlichen: eine einjährige Interim-Analyse
Literatur
1.
Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001;163:1723–9.CrossRefPubMed
2.
Schmidt B, Asztalos EV, Roberts RS, Robertson CM, Sauve RS, Whitfield MF, Trial of Indomethacin Prophylaxis in Preterms (TIPP) Investigators. Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the Trial of Indomethacin Prophylaxis in Preterms. JAMA. 2003;289:1124–9.CrossRefPubMed
3.
Marter LJ van, Kuban KC, Allred E, Bose C, Dammann O, O’Shea M, Laughon M, Ehrenkranz RA, Schreiber MD, Karna P, Leviton A, ELGAN Study Investigators. Does bronchopulmonary dysplasia contribute to the occurrence of cerebral palsy among infants born before 28 weeks of gestation? Arch Dis Child Fetal Neonatal Ed. 2011;96:F20–F29.CrossRefPubMed
4.
Stichtenoth G, Demmert M, Bohnhorst B, Stein A, Ehlers S, Heitmann F, Rieger-Fackeldey E, Olbertz D, Roll C, Emeis M, Mögel M, Schiffmann H, Wieg C, Wintgens J, Herting E, Göpel W, Härtel C. Major contributors to hospital mortality in very-low-birth-weight infants: data of the birth year 2010 cohort of the German Neonatal Network. Klin Padiatr. 2012;224:276–81.CrossRefPubMed
5.
Gortner L, Misselwitz B, Milligan D, et al. Rates of bronchopulmonary dysplasia in very preterm neonates in Europe: results from the MOSAIC cohort. Neonatology. 2011;99:112–7.CrossRefPubMed
6.
Smith VC, Zupancic JA, McCormick MC, Croen LA, Greene J, Escobar GJ, Richardson DK. Trends in severe bronchopulmonary dysplasia rates between 1994 and 2002. J Pediatr. 2005;146:469–73.CrossRefPubMed
7.
Thomas W, Speer CP. Management of infants with bronchopulmonary dysplasia in Germany. Early Hum Dev. 2005;81:155–63.CrossRefPubMed
8.
Mercier JC, Hummler H, Durrmeyer X, Sanchez-Luna M, Carnielli V, Field D, Greenough A, Overmeire B van, Jonsson B, Hallman M, Baldassarre J, EUNO Study Group. Inhaled nitric oxide for prevention of bronchopulmonary dysplasia in premature babies (EUNO): a randomised controlled trial. Lancet. 2010;376:346–54.CrossRefPubMed
9.
Watterberg KL, American Academy of Pediatrics. Committee on fetus and newborn policy statement – postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia. Pediatrics. 2010;126:800–8.CrossRefPubMed
10.
Röhr SB, Sauer H, Gortner L, Gräber S, Meyer S. Cardiovascular and metabolic side effects associated with hydrocortisone and dexamethasone use in VLBW infants: a single-centre experience. Acta Paediatr. 2013;102:e436.CrossRefPubMed
11.
Biesalski HK, Nohr I. Importance of vitamin A for lung function and development. Mol Aspects Med. 2003;24:431–40.CrossRefPubMed
12.
Metzler MD, Snyder JM. Retinoic acid differentially regulates expression of surfactant associated proteins in human fetal lung. Endocrinology. 1993;133:1990–8.CrossRefPubMed
13.
Zile MH. Function of vitamin A in vertebrate embryonic development. J Nutr. 2001;131:705–8.PubMed
14.
Darlow BA, Graham PJ. Vitamin A supplementation to prevent mortality and short- and long-term morbidity in very low birthweight infants. Cochrane Database Syst Rev. 2011;10:CD000501.
15.
Tyson JE, Wright LL, Oh W, Kennedy KA, Mele L, Ehrenkranz RA, Stoll BJ, Lemons JA, Stevenson DK, Bauer CR, Korones SB, Fanaroff AA. Vitamin A supplementation for extremely-low-birth-weight infants. N Engl J Med. 1999;340:1962–8.CrossRefPubMed
16.
Kaplan HC, Tabangin ME, McClendon D, Meinzen-Derr J, Margolis PA, Donovan EF. Understanding variation in vitamin A supplementation among NICUs. Pediatrics. 2010;126:e367–e373.CrossRefPubMed
17.
Agostoni C, Buonocore G, Carnielli VP, De Curtis M, Darmaun D, Decsi T, et al. Enteral nutrient supply for preterm infants: commentary from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition Committee on Nutrition. J Pediatr Gastroenterol Nutr. 2009;50:85–91.CrossRef
18.
Wardle SP, Hughes A, Chen S, Shaw NJ. Randomised controlled trial of oral vitamin A supplementation in preterm infants to prevent chronic lung disease. Arch Dis Child Fetal Neonatal Ed. 2001;84:F9–F13.CrossRefPubMedPubMedCentral
19.
Gadhia MM, Cutter GR, Abman SH, Kinsella JP. Effects of early inhaled nitric oxide therapy and vitamin A supplementation on the risk for bronchopulmonary dysplasia in premature newborns with respiratory failure. J Pediatr. 2014;164:744–8.CrossRefPubMed
20.
Meyer S, Gortner L. NeoVitaA Trial Investigators Early postnatal additional high-dose oral vitamin A supplementation versus placebo for 28 days for preventing bronchopulmonary dysplasia or death in extremely low birth weight infants. Neonatology. 2014;105:182–8.CrossRefPubMed
Metadaten
Titel
Up-date on the NeoVitaA Trial: Obstacles, challenges, perspectives, and local experiences
verfasst von
Prof. Dr. med. Sascha Meyer
Prof. Dr. med. Ludwig Gortner
NeoVitaA Trial investigators
Publikationsdatum
26.09.2016
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 11-12/2017
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-016-0500-z

Weitere Artikel der Ausgabe 11-12/2017

The role of EEG recordings in children undergoing cardiac surgery for congenital heart disease

  • original article

The role and limitations of Cochrane reviews at the bedside: a systematic synopsis of five pediatric subspecialties

  • original article

Metatarsalgie: Differentialdiagnose und Therapie

  • übersicht

Episodes of hypo- and hypercapnia in a cohort of mechanically ventilated VLBW infants: the role of adequate staffing

  • short communication

An unusual cause of vertigo and headache in childhood

  • main topic

Role of multiplex PCR analysis in children with febrile seizures

  • original article